Avenue Therapeutics Announces Publication of a Review of IV Tramadol
September 09 2020 - 8:00AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company
focused on the development of intravenous (“IV”) tramadol for the
U.S. market, today announced that a publication entitled “IV
tramadol: A novel option for US patients with acute pain—A review
of its pharmacokinetics, abuse potential and clinical safety
record” has been published in the peer-reviewed journal, Journal of
Opioid Management, and can be accessed here.
This paper provides a review of the
pharmacokinetics (“PK”) of the IV tramadol dosing regimen intended
for the U.S., its abuse potential as documented in the literature,
its safety record in clinical practice outside the U.S. and
discusses how IV tramadol may become a useful option for patients
with acute pain in the U.S. The review includes the
following:
- The PK profile of the IV tramadol
dosing regimen, which results in similar overall steady‐state Cmax
(peak serum concentration) and AUC (Area Under the Curve) for
tramadol, and a lower Cmax, AUC, as well as slower onset of M1
(tramadol’s primary metabolite and a more potent µ agonist than the
parent compound), as compared to oral tramadol 100 mg administered
once every 6 hours.
- A focused and targeted review of
the literature regarding tramadol abuse in the U.S. where oral
tramadol is available and in countries where oral and IV tramadol
are approved. It found that the abuse potential for IV tramadol is
highly likely to be even lower than that of oral tramadol and much
lower than other opioids, and that the abuse potential for oral
tramadol is low in comparison to more potent opioids such as
morphine, oxycodone, and hydrocodone.
- An examination of the most
frequently reported adverse events (“AEs”) associated with IV
tramadol use in the VigiBase, the WHO global database of Individual
Case Safety Reports. Despite the potential limitations of this
spontaneous reporting database, IV tramadol in general appears to
be comparable to oral tramadol with respect to AE reports in all
regions.
The paper concluded that the availability of IV
tramadol as an alternative to pure µ opioid analgesics should be a
valuable option for U.S. clinicians who treat acute pain in the
hospital setting.
About Avenue TherapeuticsAvenue Therapeutics is
a specialty pharmaceutical company whose mission is to develop IV
tramadol, a potential alternative that could reduce the use of
conventional opioids, for patients suffering from acute pain in the
U.S. Avenue is headquartered in New York City and was founded by
Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit
www.avenuetx.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to us obtaining
regulatory approval from the FDA for our product candidate, risks
relating to the COVID-19 outbreak and its potential impact on our
employees’ and consultants’ ability to complete work in a timely
manner, risks relating to our growth strategy; risks relating to
the results of research and development activities; risks relating
to the timing of starting and completing clinical trials; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
Contacts: Jaclyn Jaffe and William BegienAvenue
Therapeutics, Inc. (781) 652-4500ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024